WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock Ownership - Who owns Dianthus Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Dianthus Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Fairmount Funds Management LLCDirector2024-01-22834,334$12.00
$10.01MBuy
Leon O. Moulder Jr.Director2024-01-22166,667$12.00
$2.00MBuy
Lei MengDirector2024-01-221,500,000$12.00
$18.00MBuy
Fairmount Funds Management LLCDirector2023-09-2924,670$13.63
$336.25kBuy
Fairmount Funds Management LLCDirector2023-09-2630,000$13.15
$394.50kBuy
Simrat RandhawaChief Medical Officer2023-09-222,000$13.20
$26.40kBuy
Simrat RandhawaChief Medical Officer2023-09-212,000$13.20
$26.40kBuy
Fairmount Funds Management LLCDirector2023-09-1930,000$13.20
$396.00kBuy
Fairmount Funds Management LLCDirector2023-09-139,367$11.76
$110.16kBuy
Fairmount Funds Management LLCDirector2023-09-1214,887$10.85
$161.52kBuy

1 of 1

DNTH insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DNTH insiders and whales buy or sell their stock.

DNTH Shareholders

What type of owners hold Dianthus Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC18.83%5,525,674$118.80MInsider
Bruce Booth14.03%4,117,125$88.52MInsider
Blake Byers11.38%3,339,137$71.79MInsider
Gv 2016 GP LLC11.38%3,339,137$71.79MInsider
Atlas Venture Fund X LP10.73%3,148,399$67.69MInsider
Third Rock Ventures Iv LP10.42%3,058,204$65.75MInsider
Lei Meng9.26%2,717,554$58.43MInsider
Fmr LLC7.56%2,218,212$47.69MInstitution
Fairmount Funds Management LLC6.57%1,928,503$41.46MInstitution
5am Venture Management LLC5.02%1,472,264$31.65MInstitution

1 of 3

DNTH vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DNTH24.91%75.09%Net Buying
MESO0.14%0.00%
HLVX65.85%34.15%Net SellingNet Selling
COGT87.38%11.29%Net BuyingNet Buying
YMAB46.22%39.32%Net BuyingNet Selling
View Top Biotech Stocks

Dianthus Therapeutics Stock Ownership FAQ

Who owns Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ: DNTH) is owned by 35.07% institutional shareholders, 105.74% Dianthus Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Dianthus Therapeutics shareholder, owning 5.53M shares representing 18.83% of the company. Fairmount Funds Management LLC's Dianthus Therapeutics shares are currently valued at $118.80M.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.